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Abstract 1 
Canine mast cell tumours often express mutations in KIT exon 11 that result in 2 
autophosphorylation and constitutive activation of the c-kit receptor, even in the absence of 3 
stem cell factor, its natural ligand. Such activating mutations have been associated with more 4 
aggressive neoplastic disease. The aim of the current study was to determine whether small 5 
inhibitory RNA (SiRNA) molecules could be used to specifically knock-down canine KIT 6 
expression. Canine beta-2 microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase 7 
(GAPDH) and KIT coding sequences were cloned downstream of the renilla luciferase 8 
element in the psiCHECK™-2 bi-cistronic vector, that also expresses firefly luciferase. 9 
SiRNA molecules were designed to target gene-specific sequences and were co-transfected 10 
with plasmid DNA into Chinese hamster ovary (CHO) cells. Renilla and firefly luciferase 11 
activity was subsequently measured using the Dual-GLO
®
 Luciferase Assay (Promega). 12 
Using this luciferase reporter system, canine housekeeping gene-specific SiRNA molecules 13 
demonstrated knockdown of their targets (72.0% knockdown for B2M and 94.5% knockdown 14 
for GAPDH). An SiRNA molecule targeting exon 2 of canine KIT successfully knocked-15 
down renilla luciferase expression of a KIT
26-407
 construct (90.8% knockdown). An SiRNA 16 
molecule targeting a common 48 base-pair in-tandem duplication mutation in KIT exon 11 17 
selectively knocked down expression of the KIT
1569-1966mutant
 construct (93.1% knockdown) 18 
but had no effect on the KIT
1569-1918wild-type
 construct. The results show that RNA interference 19 
can be used to inhibit canine KIT mRNA expression and has the potential to selectively target 20 
the mutant version of KIT that is expressed by some malignant mast cells. 21 
22 
 3 
1. Introduction 1 
Mast cell tumours (MCT) are the most common skin malignancy in dogs and are thought to 2 
arise from neoplastic transformation of tissue mast cells, although the precise aetiology is 3 
uncharacterised (reviewed by Dobson and Scase, 2007, Welle et al., 2008). In order to 4 
become malignant, mast cells must be able to resist those mechanisms associated with 5 
programmed cell death, to allow survival and proliferation. Developing a greater 6 
understanding of how such cells prevent apoptosis might enable us to design more rational 7 
treatment strategies for this type of cancer. 8 
Mast cell viability in healthy tissues is regulated by stem cell factor (SCF) via its 9 
action on the KIT receptor (CD117), which has tyrosine kinase activity (Qiu et al., 1988). 10 
SCF binding to KIT is thought to provide survival signals, by inhibiting apoptosis through 11 
modulation of apoptosis-regulatory proteins (Kitamura et al., 1978, Kitamura & Go, 1979, 12 
Galli & Kitamura, 1987, Tsai et al., 1991, Galli et al., 1994, Serve et al., 1995, Linnekin et 13 
al., 1997, Vosseller et al., 1997, Timokhina et al., 1998, Brazis et al., 2000, Taylor & 14 
Metcalfe, 2000). In human mast cells, overexpression of Bcl-2 or Bcl-xL, protects against 15 
programmed cell death and is thought to contribute to oncogenesis (Cerveró et al., 1999, 16 
Hartmann et al., 2003). Mutations in the KIT gene are found in 15-50% of canine MCT, 17 
which typically consist of in-tandem duplications, located in or around exon 11 (London et 18 
al., 1999, Ma et al., 1999, Reguera et al., 2000, Downing et al., 2002, Reguera et al., 2002, 19 
Zemke et al., 2002, Turin et al 2006, Webster et al., 2006 A & B). When expressed, such 20 
mutations often result in autophosphorylation of the cytoplasmic kinase domain of the 21 
receptor protein, leading to constitutive activation, even in the absence of SCF (London et 22 
al., 1999, Ma et al., 1999, Pryer et al., 2003). The C2 mastocytoma cell line, which is 23 
commonly used to study canine malignant mast cell biology in vitro, expresses a 48 base-24 
pair in-tandem duplication (London et al., 1999, Ma et al., 1999), although the precise 25 
 4 
location, nature and size of mutations can vary between different MCTs (Reguera et al., 1 
2000, Downing et al., 2002, Pryer et al., 2003, Riva et al., 2005, Roskoski et al., 2005, Turin 2 
et al., 2006, Webster et al., 2006A, Letard et al., 2008). 3 
KIT activating mutations have been shown to be associated with MCT of a more 4 
aggressive phenotype, which is likely due to increased proliferation and resistance to 5 
apoptosis (Hirota et al., 1998, Corless et al., 2004, Gleixner et al., 2007, Webster et al., 6 
2007, Letard et al., 2008). This has led to several investigations into the therapeutic 7 
potential of receptor tyrosine kinase inhibitors (RTKi), designed to specifically target this 8 
molecule. There are currently two drugs (masitinib, Masivet
®
, AB Science; toceranib, 9 
Palladia
®
, Pfizer) that have recently been licensed for canine MCT. However, these 10 
compounds can also impact on other receptor tyrosine kinases (Rubin et al., 2001, Hayes & 11 
Thor, 2002, Humbert et al., 2009, London et al., 2009), potentially leading to adverse 12 
effects. More specific targeting of the mutant KIT receptor is likely to be more selective in 13 
having anti-cancer effects. 14 
RNA interference can be used to target specific mRNA for degradation (Spee et al., 15 
2006, Tsuchiya et al., 2006, Watanabe et al., 2009. Thus, gene expression can be selectively 16 
silenced, preventing production of the encoded protein, which allows experiments to be 17 
designed to determine the role of that specific gene product on cellular function. The aim of 18 
the current study was to determine whether small inhibitory RNA (SiRNA) molecules could 19 
be designed to specifically knock-down canine KIT expression. In particular we aimed to 20 
design novel SiRNA molecules that specifically targeted the mutant KIT expressed by C2 21 
cells that would spare expression of the wild-type receptor. However, since C2 cells proved 22 
to be resistant to chemical transfection, we used a reporter gene assay to assess the ability of 23 
canine KIT-specific SiRNA molecules to knock-down their target. 24 
 25 
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 1 
2. Materials and Methods 2 
2.1 Plasmid DNA constructs and SiRNA molecules 3 
Partial coding regions for selected canine genes were amplified by PCR from cDNA prepared 4 
from the C2 canine mastocytoma cell line (a generous gift from Dr B. Helm, University of 5 
Sheffield; originally generated by Prof W. Gold, University of California (Lazarus et al., 6 
1986), which expresses both wild-type KIT as well as a KIT exon 11 mutation (Figure 1). 7 
PCR products representing canine glyceraldehyde-3-phosphate dehydrogenase; GAPDH
520-971
 8 
(sense primer: ACCACCGTCCATGCCATCAC; antisense primer: 9 
TCCACCACCCGGTTGCTGTA; 452bp amplicon), beta-2 microglobulin; B2M
47-379
 (sense 10 
primer: TCCTCATCCTCCTCGCT; antisense primer: GTCAGTTGTCTCGGTCCCAC; 11 
333bp amplicon), KIT
26-407
 (KIT1: sense primer: ATTTTCTCTGCGTCCTGCTC; antisense 12 
primer: ACCAGCGTATCATTGCCTTC; 382bp amplicon), KIT
1569-1920wild-type 
and KIT
1569-
13 
1968mutant 
(KIT2: sense primer: CCTGTTCACACCTTTGCTGA; antisense primer 14 
TAGGGCTTCTCGTTCGGTTA; 352bp amplicon for wild-type, 400bp amplicon for mutant) 15 
were initially cloned into the pSC-A vector (Stratagene, La Jolla, CA). Plasmid DNA from 16 
recombinant clones was sequenced to confirm the integrity of the inserts, which were then 17 
sub-cloned into the psi-CHECK™-2 bi-cistronic vector (Promega, Southampton, UK), 18 
downstream of the renilla luciferase element using NotI and XhoI restriction sites. Plasmid 19 
DNA was then extracted from recombinant E.coli using the GenElute™ Endotoxin-free 20 
Miniprep Kit (Sigma, Poole, UK) in preparation for transfection studies. The SiRNA 21 
molecules used in the study are shown in Table 1. In addition, a scrambled SiRNA molecule 22 
(AllStars Negative Control SiRNA, Qiagen, Crawley, UK) was used as a negative control. 23 
 24 
2.2 Cell culture and transfections 25 
 6 
Chinese hamster ovary (CHO) cells were maintained in 75 cm
2
 flasks of culture medium 1 
consisting of Minimal Essential Medium (Sigma. Poole, UK) supplemented with 10 mM 2 
Glutamax-1 (Invitrogen) 10% foetal bovine serum (Serotec, Kidlington, UK) and 25 μg/ml 3 
gentamicin (Sigma). Cells for transfection studies were plated out in triplicate wells in 4 
Corning 96 well clear bottom, white microtitre plates (Sigma) at 1 x10
4
 cells in a 100 μl 5 
volume of culture medium lacking serum and antibiotics. Cells in each well were transfected 6 
with 200 ng plasmid DNA and 5 pmol SiRNA using Lipofectamine 2000™ (Invitrogen) 7 
according to the manufacturer’s instructions. Plates were incubated for 4 h then the complex-8 
containing medium was replaced with culture medium lacking antibiotics. 9 
 10 
2.3 Luciferase assay 11 
Twenty four hours after transfection, cells were assayed for both firefly and renilla luciferase 12 
activity using the Dual-GLO
®
 Luciferase Assay System (Promega). Briefly, cells were lysed 13 
and the firefly luciferase substrate added (50 μl per well Dual-GLO® Substrate/Buffer). After 14 
15 min, luciferase activity was measured using a luminometer (Spectramax M2, Molecular 15 
Devices). Next the renilla luciferase substrate was added (50 μl per well Stop & GLO® 16 
Substrate/Buffer) and the luminescence measured after a further 15 min incubation. The 17 
renilla / firefly luciferase ratio was calculated from the mean luminescence values of triplicate 18 
wells, after blanking against values from untransfected cells. The percentage knockdown 19 
using test SiRNA molecules was calculated compared to the control scrambled SiRNA and 20 
data are shown as the mean of three experimental replicates. 21 
 22 
3. Results 23 
3.1 Knock-down in expression of canine housekeeping genes and KIT
wild-type
 24 
 7 
Since there are few studies using SiRNA to specifically knock-down canine gene expression, 1 
several SiRNA molecules were initially assessed that were designed to target housekeeping 2 
genes. Using a renilla luciferase SiRNA molecule as a positive control, efficient knock-down 3 
of canine GAPDH was demonstrated, although SiRNA molecules targeting beta-2 4 
microglobulin were less efficient (Table 2). A validated human KIT SiRNA molecule (which 5 
has complete identity to the target sequence in canine KIT) was evaluated and showed >90% 6 
knock-down efficiency (Table 2). 7 
 8 
3.2 Knock-down in expression of the C2 KIT mutant 9 
The mutation present in the KIT gene expressed by C2 cells consists of a 48 bp in-tandem 10 
duplication in exon 11. Since this generates a unique sequence at the 5’ junction of the 11 
insertion, an SiRNA molecule was designed that spanned this region (Figure 1, Table 1). 12 
When tested against constructs containing either the wild-type sequence or the mutant 13 
version, this SiRNA molecule demonstrated efficient knock-down when using the KIT2
mutant
 14 
construct (mean 93.1% knock-down) but had little effect on the KIT2
wild-type 
construct (mean -15 
2.98% knock-down) (Figure 2). 16 
 17 
4. Discussion 18 
Recent advances in treatment of canine MCT have focused on the use of RTKi (e.g 19 
masitinib and toceranib). However, these compounds are not specific for KIT and also inhibit 20 
other receptor tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR) and 21 
vascular growth factor receptor (VEGFR2) (Rubin et al., 2001, Hayes & Thor, 2002, Humbert 22 
et al., 2009, London et al., 2009). Although the lack of specificity might enhance the anti-23 
cancer efficacy of these drugs, this could also increase the risk of adverse effects in the 24 
patient. In addition, these RTKi will not have specific effects on malignant mast cells, as they 25 
 8 
will also inhibit wild-type KIT, expressed by tissue mast cells and other cell types including 1 
haematopoietic stem cells and melanocytes (Galli et al., 1994, Serve et al., 1995, Linnekin et 2 
al., 1997, Vosseller et al., 1997, Timokhina et al., 1998, Brazis et al., 2000) Molecular 3 
techniques, such as gene silencing by RNA interference, offer an alternative, more specific 4 
method for targeting mutant KIT that might be applicable for canine MCT, as well as for 5 
canine gastrointestinal stromal cell tumours that also commonly express KIT mutations in 6 
humans (Lasota et al., 2003, Steigen et al., 2007, Du et al., 2008).  7 
There are relatively few published papers describing RNA interference in the canine 8 
system. In terms of studying the biology of canine malignant cells, siRNA targeting of 9 
apoptosis-modulator molecules including Bcl-2 (Watanabe et al., 2009), Bcl-xL (Tsuchiya et 10 
al., 2006) and XIAP (Spee et al., 2006) have previously been undertaken in canine cancer cell 11 
lines. Knockdown of canine (housekeeping) gene(s), not involved in malignancy, would be 12 
useful as negative controls for RNA interference studies, although there were no published 13 
reports of their use prior to commencing the current study. 14 
To investigate the biological effect of KIT RNA interference, the C2 canine 15 
mastocytoma cell line was chosen for in vitro studies. The C2 cells used in the current study 16 
expressed both wild-type and mutant KIT mRNA (Figure 1), although wild-type KIT seems 17 
to be absent in the C2 cells used in some (Ma et al., 1999) but not all previous studies 18 
(London et al., 1999). Since no KIT siRNA molecules had been validated for the dog, several 19 
human KIT siRNAs, that had been shown to increase apoptosis in human cell lines (Lefevre 20 
et al., 2004; Li et al., 2007; Sikarwar & Reddy 2008) were assessed for sequence identity with 21 
the canine KIT sequence. One commercially available KIT SiRNA molecule (Silencer
®
 22 
SiRNA 35, Ambion), which demonstrated complete sequence identity between human and 23 
canine target sequences, was identified. For the other targets (GAPDH, B2M and KIT exon 24 
11 mutation), novel SiRNA molecules were designed for evaluation. 25 
 9 
Chemical transfection of C2 cells proved to be problematic, despite repeated attempts 1 
using various transfection reagents and protocols (data not shown). Therefore, to allow 2 
investigation of the activity of the siRNA molecules to specifically interfere with their target 3 
canine mRNA, an alternative assay was established. This assay was based on use of the 4 
psiCHECK-2
TM
 reporter system in the CHO cell line, which had been shown to be readily 5 
transfectable with Lipofectamine
TM
 2000. This reporter assay allows rapid and relatively 6 
simple assessment of the activity of novel SiRNA molecules against their target sequences, 7 
prior to evaluation of RNA interference in the target cells. One disadvantage, however, is that 8 
it does not provide information as to any off-target effects of the SiRNA molecule. 9 
Co-transfection of CHO cells with recombinant plasmid DNA containing canine target 10 
sequences and either scrambled or targeted siRNA molecules demonstrated that GAPDH and 11 
KIT
exon2
 siRNAs induced a knockdown efficiency of greater than 80%, although the canine 12 
B2M SiRNA molecules were somewhat less effective. The increase in firefly luciferase 13 
activity seen in CHO cells co-transfected with plasmid DNA with scrambled siRNA, 14 
compared to those cells transfected with plasmid DNA alone, might be explained by the 15 
greater amount of transfection reagent used, leading to increased transfection efficiency. A 16 
further increase in firefly luminescence was seen in CHO cells co-transfected with targeted 17 
siRNA compared to scrambled siRNA. This pattern of reactivity might be explained if firefly 18 
and renilla luciferase mRNA compete for translation. Thus, following successful targeting of 19 
the renilla-fusion mRNA for destruction, this could lead to enhanced firefly luciferase protein 20 
expression. 21 
The KIT
exon2
 SiRNA molecule is not specific to the mutant KIT sequence and would 22 
be expected to knock-down both wild-type and mutant KIT mRNAs. Therefore, a novel 23 
canine KIT SiRNA molecule was designed, that targeted the 5’ junction of the insertion 24 
mutation to determine whether it might be possible to specifically knock-down the mutant 25 
 10 
version, while sparing expression of wild-type KIT. Both firefly and renilla luciferase activity 1 
were consistently lower when using the psiCHECK-2
TM
 construct containing canine mutant 2 
KIT, compared to the native vector or vector containing wild-type KIT sequences. Endotoxin 3 
contamination of the plasmid DNA was considered, but a new batch of plasmid DNA 4 
demonstrated the same response. The explanation for this reduced efficiency of luciferase 5 
activity with this particular construct remains unclear. Despite this, the KIT
exon11mut
 SiRNA 6 
molecule demonstrated specificity of activity against the mutant KIT construct, without 7 
affecting expression from the construct containing the equivalent wild-type KIT sequence. 8 
 In the current study, we have validated several canine gene-specific SiRNA 9 
molecules. These can now be assessed in canine cell lines and it is anticipated that alternative 10 
delivery systems (e.g. electroporation) will allow evaluation of these molecules in the C2 cell 11 
line. We have shown as “proof-of-concept” that SiRNA molecules can be designed to 12 
specifically target KIT mutations, although the heterogeneity of mutations seen in canine 13 
MCT means that it is unlikely that a single SiRNA molecule could be designed that would be 14 
effective in all cases. 15 
16 
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Fig. 1. The C2 cell line expresses both wild-type KIT and a KIT exon 11 mutant. (a) cDNA 1 
was prepared from C2 cells and used as the template for PCR using primers spanning KIT 2 
exon 11. PCR products were separated by 2% agarose gel electrophoresis. Anticipated 3 
amplicon size = 352bp for wild-type KIT and 400bp for the mutant version, which contains a 4 
48bp in-tandem duplication. MWt = 200bp molecular weight marker. (b) Sequence of KIT 5 
mutation in C2 cells. Partial genomic DNA sequence is shown with exon 11 highlighted. The 6 
48 bp mutation is shown in bold and the region targeted by the SiRNA molecule is 7 
underlined. 8 
 9 
Fig. 2. Knockdown efficiency of an SiRNA molecule that targets the C2 KIT mutation. 10 
Recombinant psiCHECK-2 plasmid DNA was generated containing either the 5’ region of 11 
canine KIT (KIT1) or the region containing exon 11 (KIT2) of either the wild-type or mutant 12 
version of the gene. Triplicate wells of CHO cells were transfected with recombinant 13 
psiCHECK-2 plasmid DNA and selected wells were co-transfected with scrambled siRNA 14 
(negative control), renilla SiRNA (positive control) or siRNA targeted to KIT (either exon 2 15 
or the in-tandem duplication mutation within exon 11). Both firefly and renilla luminescence 16 
were measured after 24 h incubation. The renilla/firefly luciferase ratio are shown which 17 
represents the knock-down capability of the SiRNA molecule on the target mRNA. A 18 
representative experiment is shown of three replicates. 19 
 20 
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Target 
gene 
Plasmid DNA construct SiRNA 
molecule 
SiRNA target 
sequence 
SiRNA source 
Renilla 
luciferase 
psiCHECK-2 Renilla tggcctttcactactcctacg Custom synthesized 
(Ambion) 
GAPDH psiCHECK-2/GAPDH
520-971 
GAPDH#1
exon8a
 ccactttgtcaagctcatt Custom synthesized 
(Ambion) 
GAPDH psiCHECK-2/GAPDH
520-971 
GAPDH#2
exon8b
 cgacatcaagaaggtagtg Custom synthesized 
(Ambion) 
B2M psiCHECK-2/B2M
47-379 
B2M#1
exon2a
 ctcccaatgagcaggatga Custom synthesized 
(Sigma) 
B2M psiCHECK-2/B2M
47-379 
B2M#2
exon2b
 ccgtgtaaagcatgttact Custom synthesized 
(Sigma) 
KIT psiCHECK-2/KIT
26-407 
KIT
exon2
 ggctcttctcaaccatctg Silencer
®
 SiRNA 35 
(Ambion) 
KIT psiCHECK-2/KIT
1569-1966mutant
 KIT
exon11mut
 agaacatacccaacacagc Custom synthesized 
(Ambion) 
 2 
Table 1. Plasmid DNA constructs and SiRNA molecules used in knock-down studies. 3 
 4 
14 
 
Transfection conditions 
Exp #1 Exp #2 Exp #3 
 
Mean 
Firefly  
(LU) 
Renilla 
(LU) KD (%) 
Firefly 
(LU) 
Renilla  
(LU) KD (%) 
Firefly 
(LU) 
Renilla 
(LU) KD (%) KD (%) 
           
psiCHECK
TM
-2 2981 1493  1023 550  407 372   
psiCHECK
TM
-2 + Scrambled siRNA 7528 3307  2662 1474  1536 1316   
psiCHECK
TM
-2 + Renilla siRNA 10474 240 94.8 2794 91 94.1 3014 19 99.3 96.1 
           
psiCHECK
TM
-2/B2M  2505 1586  2137 1305  1873 998   
psiCHECK
TM
-2/B2M + Scrambled siRNA 9952 5278  7329 3733  7001 3509   
psiCHECK
TM
-2/B2M + B2M#1 siRNA 6175 1858 43.3 5657 1296 55.0 5593 1206 57.0 51.8 
psiCHECK
TM
-2/B2M + B2M#2 siRNA 8532 1300 71.3 7452 1126 70.3 7478 958 74.4 72.0 
           
psiCHECK
TM
-2/GAPDH  369 1045  535 896  474 703   
psiCHECK
TM
-2/GAPDH + Scrambled siRNA 1236 2620  843 1034  1102 1133   
psiCHECK
TM
-2/GAPDH + GAPDH#1 siRNA 1503 101 96.8 1354 139 91.6 1774 90 95.07 94.5 
psiCHECK
TM
-2/GAPDH + GAPDH#2 siRNA 2162 767 83.3 2052 489 80.6 2225 466 79.63 81.2 
           
psiCHECK
TM
-2/KIT1  524 1105  506 751  619 682   
psiCHECK
TM
-2/KIT1 + Scrambled siRNA 1512 2580  1130 1199  1390 1325   
psiCHECK
TM
-2/KIT1 + KITexon2 siRNA 1933 241 92.7 1526 202 87.5 2368 174 92.28 90.8 
 
Table 2. Knockdown efficiency of canine housekeeping gene and KIT SiRNA molecules. Triplicate wells of CHO cells were transfected 
with native or recombinant psiCHECK-2 plasmid DNA and co-transfected with either scrambled siRNA, siRNA targeted to renilla luciferase, or 
SiRNA targeting the inserted canine sequence. Both firefly and renilla luciferase activity were measured after 24 h incubation. Mean 
luminescence data are shown, following subtraction of the luminescence values of untransfected CHO cells. Knockdown efficiency of targeted 
siRNA was calculated compared to scrambled siRNA. GAPDH = glyceraldehyde-3-phosphate dehydrogenase, B2M = 2microglobulin, Exp = 
experimental replicate, LU = luminescence units, KD (%) = percentage knockdown efficiency. 
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TCTCTACCCTAAGTGCTATAATGATCGAAATGTTATTCATTAAAAGATG15 
ATCTGTCTCTCTTTTCTCCCCCCACCAGAAACCCATGTATGAAGTACAG16 
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CGTGTAACAATGACTTTAGGGAACCCCATTAGCTTCCTTTGTTCTGTTC21 
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